By network meta- analysis , sildenafil seems to be the most efficiency with a slightly higher rate of treatment-emergent adverse events ( TEATs ) , whereas tadalafil had the lowest TEATs .
Compared with placebo , PDE5-Is manifested significantly improved treatment outcomes .
Overall , regular regimen demonstrated statistically pronounced better potency than on-dem and .
Phosphodiesterase type-5 inhibitors ( PDE5-Is ) have been recommended as first line therapy for erectile dysfunction for patients received nerve-sparing radical prostatectomy for prostate cancer .
We examed the efficiency of PDE5-Is and considered the optimal application .
Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.
OBJECTIVES To examine the therapeutic effects of tadalafil on erectile dysfunction ( ED ) at 24 and 36 hours after dosing . METHODS A multicenter , r and omized , double-blind , placebo-controlled , parallel-group study of 348 men ( mean age 57 years ) with ED was conducted in Europe and the United States . Patients were stratified by baseline severity of ED using the Erectile Function domain score of the International Index of Erectile Function and then r and omly allocated within the severity group to receive tadalafil 20 mg ( n = 175 ) or placebo ( n = 173 ) . Subsequently , participants were r and omly assigned to two 4-week treatment intervals , during which they were requested to attempt sexual intercourse approximately 24 or 36 hours after tadalafil or placebo dosing . The primary outcome measure was the proportion of successful sexual intercourse attempts ( completed to ejaculation ) according to patient self-report using the Sexual Encounter Profile diary . RESULTS Of the 348 patients , 327 ( 94 % ) completed the trial ( 163 of 175 in the  tadalafil group and 164 of 173 in the placebo group ) . Thirty-six hours after tadalafil dosing , 59.2 % of intercourse attempts were successful versus 28.3 % in the placebo group ( P < 0.001 ) . The proportion of successful intercourse attempts at approximately 24 hours after treatment was also significantly greater with tadalafil ( 52.9 % ) than with placebo ( 29.1 % ; P < 0.001 ) . Tadalafil was well tolerated . The incidences of four treatment-emergent adverse events were significantly greater in the tadalafil group than in the placebo group ( all P < 0.05 ) : headache , flushing , dyspepsia , and myalgia . CONCLUSIONS Tadalafil 20 mg is an effective and well-tolerated treatment for ED that has a period of responsiveness of up to 36 hours
By network meta- analysis , sildenafil seems to be the most efficiency with a slightly higher rate of treatment-emergent adverse events ( TEATs ) , whereas tadalafil had the lowest TEATs .
Compared with placebo , PDE5-Is manifested significantly improved treatment outcomes .
Overall , regular regimen demonstrated statistically pronounced better potency than on-dem and .
Phosphodiesterase type-5 inhibitors ( PDE5-Is ) have been recommended as first line therapy for erectile dysfunction for patients received nerve-sparing radical prostatectomy for prostate cancer .
We examed the efficiency of PDE5-Is and considered the optimal application .